HPV vaccine: Cervarix

Cervarix™, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions

(2014) David Le Tallec et al.   Human vaccines & immunotherapeutics

Human papillomaviruses (HPV) vaccines: implementation and communication issues

(2011) M. A. Kane   JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

(2010) Dominique Descamps et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Human Papillomavirus Infection and Cervical Disease in Human Immunodeficiency Virus-1–Infected Women

(2010) Lynette Denny et al.   OBSTETRICS AND GYNECOLOGY

Raising awareness of human papillomavirus and cervical cancer prevention: the need for clinical education

(2009) Anne Szarewski   Future Virology

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

(2009) Xavier Castellsagué et al.   GYNECOLOGIC ONCOLOGY

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

(2009) Cosette M. Wheeler et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

(2009) John T. Schiller et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

HPV vaccine for all

(2009) Karin B Michels et al.   LANCET

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Clinician's guide to human papillomavirus immunology: knowns and unknowns

(2009) Mark H Einstein et al.   LANCET INFECTIOUS DISEASES

Booster Vaccinations: Can Immunologic Memory Outpace Disease Pathogenesis?

(2009) M. E. Pichichero   PEDIATRICS

Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis

(2008) J. Koshiol et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

HPV and cervical cancer: screening or vaccination?

(2008) F X Bosch et al.   BRITISH JOURNAL OF CANCER

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

(2008) V M H Coupé et al.   BRITISH JOURNAL OF CANCER

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

(2008) David Jenkins   GYNECOLOGIC ONCOLOGY

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

(2008) Tino F. Schwarz et al.   GYNECOLOGIC ONCOLOGY

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

(2008) F. Xavier Bosch et al.   VACCINE

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

(2008) Thomas Verstraeten et al.   VACCINE

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

(2008) John T. Schiller et al.   VACCINE

Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions

(2008) Anna R. Giuliano et al.   VACCINE

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

(2008) Tino F. Schwarz et al.   VACCINE

HPV vaccines: peering through the fog

(2008) Anne Szarewski   JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE